Skip to main content

Rubraca News

Rubraca (rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)

BOULDER, Colo.--(BUSINESS WIRE)--May 15, 2020 – Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets for the ...

Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer

BOULDER, Colo.--(BUSINESS WIRE)--Apr. 6, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca (rucaparib) tablets for the...

FDA Grants Accelerated Approval to Rubraca (rucaparib) for Advanced Ovarian Cancer

December 19, 2016 – The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Prostate Cancer, Ovarian Cancer

Rubraca patient information at Drugs.com